Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Ken Griffins Citadel bets 300mn against drugmaker GSK GSK plc

February 18, 2025
GSK plc, one of the leading pharmaceutical companies worldwide, is facing a significant challenge as hedge fund Citadel has placed a massive bet against the drugmaker. Ken Griffin, the founder of Citadel, recently revealed that his fund has initiated a position worth $300 million, indicating his lack of confidence in GSK's future prospects.

This move by Citadel has sent shockwaves through the investment community, as it raises concerns about GSK's performance and potential financial difficulties. While GSK has been a stalwart in the pharmaceutical industry for decades, this bet against the company suggests that some investors are skeptical about its ability to sustain growth and generate substantial returns.

Investors are advised to stay updated with the latest developments regarding GSK and closely monitor its stock performance. Seeking professional advice from experts, such as Stocks Prognosis, can help navigate the uncertainty surrounding GSK's future. Stocks Prognosis offers comprehensive analysis and forecasts on various stocks, providing valuable insights to make informed investment decisions.

As an investor, it is crucial to make calculated moves and evaluate the potential risks and rewards before taking any action. The decision to buy or sell GSK's stocks should not be taken lightly, considering the current market dynamics and the bet placed by Citadel.

Investors who have suffered losses due to their GSK investments are urged to reach out to the Portnoy Law Firm before the April 7, 2025, deadline to file a Lead Plaintiff Motion. The Portnoy Law Firm specializes in representing shareholders and can provide assistance in recovering losses related to GSK investments.

Stay informed, seek professional guidance, and consider the implications of Citadel's bet against GSK before making any investment decisions in the pharmaceutical sector.
If you want to leave a comment, then you need Login or Register





Other data for GSK

Related data

GSKJuly 17, 2025QuantWave Successfully Predicts GSK PLC Stock Movement, Achieving 7.53% Profit  ~2 min.

QuantWave, the automated forecasting platform, has once again proven its accuracy with the successful prediction of the price movement of GSK PLC stock....


GSKJune 2, 2025QuantWave Delivers 7.39% Profit with Successful GSK PLC Stock Price Target Forecast  ~2 min.

On March 21, 2025, QuantWave, the automated forecasting platform, signaled a long position for GSK PLC at a price of 38.79 $. Today, on June 2, 2025, the stock reached the predicted target price of 41....


GSKJune 2, 2025QuantWave Hits Price Target Forecast for GSK PLC, Yielding 8.78% Profit  ~1 min.

QuantWave, the automated forecasting platform, successfully achieved its price target forecast for GSK PLC, resulting in a profit of 8.78%....


GSKJune 2, 2025QuantWave Achieves GSK PLC Price Target Forecast with 6.93% Profit  ~1 min.

QuantWave, the leading automated forecasting platform, has successfully hit the price target forecast for GSK PLC, resulting in a profitable trade with a 6.93% gain....


GSKJune 2, 2025QuantWave Achieves 8.39% Profit Target Forecast for GSK PLC Stock  ~1 min.

QuantWave, an automated forecasting platform, has successfully hit a price target forecast for the stock of GSK PLC, resulting in a profit of 8.39%....


GSKJune 2, 2025QuantWave Achieves 11.28% Profit Target Forecast for GSK PLC  ~1 min.

QuantWave, the automated forecasting platform, successfully predicted a long position for GSK PLC on April 1, 2025, when the stock was trading at $37.44....


GSKJune 2, 2025QuantWave Accuracy Shines with Successful GSK PLC Price Target Forecast, Profits Surge By 9.23%  ~2 min.

As the financial markets continue to exhibit volatility, QuantWave's predictive analytics once again demonstrate their accuracy and effectiveness with the recent achievement of a price target forecast for GSK PLC. On the signal date of March 25, 2025, QuantWave's forecast indicated a long position for GSK PLC with a price of $38.14. Fast forward to June 2, 2025, and the stock had reached the targe...


GSKJune 2, 2025QuantWave Successfully Predicts GSK PLC Stock Price Target with 9.4% Profit  ~1 min.

QuantWave, the leading automated forecasting platform, achieved another remarkable forecast success with GSK PLC stock, as it accurately predicted a long position from a signal date of March 27, 2025....


GSKJune 2, 2025QuantWave's Forecast for GSK PLC Hits the Mark with 9.66% Profit  ~1 min.

On March 4th, 2025, QuantWave, a leading automated forecasting platform, issued a long signal for the stock of GSK PLC with a price target forecast of 41.66$, representing a 9....


GSKJune 2, 2025QuantWave Achieves 12.68% Profit on GSK PLC Stock Price Target Forecast  ~1 min.

QuantWave, the automated forecasting platform, successfully predicted a price target for the stock of GSK PLC, resulting in a profit of 12.68%....


AZNJanuary 9, 2025The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline in AstraZeneca PLC Lawsuit  ~1 min.

AstraZeneca PLC (NASDAQ: AZN) recently faced a class action lawsuit, and The Gross Law Firm is reminding shareholders about an upcoming lead plaintiff deadline of February 21, 2025....


REGNFebruary 2, 2025Regeneron Pharmaceuticals Inc. Faces Class Action Lawsuit  ~2 min.

Regeneron Pharmaceuticals Inc. (REGN) is currently facing a class action lawsuit filed by investors....


VJanuary 22, 2025VISA SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF 100000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Visa Inc. - V  ~1 min.

VISA SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF 100000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Visa Inc. - V Visa Inc....


GSKMarch 21, 2025GSK Lead Plaintiff Deadline Approaching - Contact Robbins LLP for Information About How to Lead the GSK PLC Class Action  ~2 min.

GSK PLC, a global pharmaceutical company, is facing a class action lawsuit....


VNovember 25, 2024V VISA SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK FOTI LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Visa Inc. - V  ~2 min.

Visa Inc., a global payment technology company, is facing a major legal battle as the Department of Justice (DOJ) filed a lawsuit against them for alleged monopoly practices....